Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 15/20 | 0.37 |
| ▸ | CDK5R1 | Q15078 | 15/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 10/20 | 0.35 |
| ▸ | CDK2 | P24941 | 10/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 10/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22031130 | 0.80 | CDK5 (0.39) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL20558119 | 0.78 | CDK5 (0.45) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL20557462 | 0.76 | CDK5 (0.43) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL16095853 | 0.73 | SMN1; SMN2 (0.43) | ALDH1A1MEN1KMT2A | |
| SCHEMBL16644962 | 0.73 | HDAC1 (0.42) | — | |
| SCHEMBL14648410 | 0.73 | SMN1; SMN2 (0.36) | ALDH1A1 | |
| SCHEMBL14037363 | 0.70 | RAB9A (0.56) | TDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL15417769 | 0.70 | SLC6A3 (0.33) | ALDH1A1 | |
| SCHEMBL28281042 | 0.70 | SLC6A3 (0.41) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL28361587 | 0.70 | ALDH1A1 (0.31) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630111-B1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS INC (US) | 2021-11-24 | — | — | EP | disclosed |
| US-11046694-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200165251-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS, INC. | 2020-05-28 | — | — | US | disclosed |
| EP-3630111-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | Entasis Therapeutics, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018208769-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS, INC. (US) | 2018-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046694-B2 | Compounds and methods for treating bacterial infections | MRPL21, CFTR, C5 | CDK5 4226/4885CDK5R1 2362/4885CCNA2 3700/4885 |
| US-20200165251-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MRPL21, CFTR, C5 | CDK5 4226/4885CDK5R1 2362/4885CCNA2 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.